AngioDynamics shareholders approve all proposals at 2024 annual meeting including equity plan amendment

ANGIODYNAMICS INC

Elected three Class III directors: Burgess, Johnson, Licitra each with >24.8M votes for, 5.99M broker non-votes.
Ratified Deloitte & Touche as FY2025 auditor with 34.1M for, 155k against, 16.5k abstain.
Advisory approval of exec compensation: 26.0M for, 1.25M against, 1.04M abstain, 5.99M broker non-votes.
Approved amended 2020 Equity Incentive Plan increasing share reserve: 23.2M for, 5.06M against, 35k abstain, 5.99M broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.